Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.69 |
| ▸ | CNR1 | P21554 | 8/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.46 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.46 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29511938 | 0.98 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL28396798 | 0.98 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL9243523 | 0.98 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL100166 | 0.98 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL2217627 | 0.98 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL2342987 | 0.98 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL2218924 | 0.98 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL6417540 | 0.98 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL3793537 | 0.98 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 | |
| SCHEMBL2216579 | 0.98 | CNR2 (0.67) | CNR2CNR1ALDH1A1DNM1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023148208-A1 | GAS LOSS REDUCING ADDITIVE FOR BEVERAGES, A BEVERAGE COMPOSITION INCLUDING THE GAS LOSS REDUCING ADDITIVE AND A METHOD OF REDUCING GAS LOSS FROM A BEVERAGE | GIVAUDAN SA (CH) | 2023-08-10 | — | — | WO | claimed |
| EP-2117527-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER'S TYPE | MED LIFE DISCOVERIES LP (CA) | 2020-06-17 | — | — | EP | claimed |
| EP-2620147-B1 | Compounds for lowering cholesterol | MED LIFE DISCOVERIES LP (CA) | 2020-06-03 | — | — | EP | claimed |
| WO-2018205038-A1 | COMPOSITIONS COMPRISING CANNABINOIDS AND TERPENES USEFUL IN THE TREATMENT OF CANCER AND VASCULAR OCULAR DISORDERS VIA INHIBITION OF HEDGEHOG SIGNALLING | TETRA BIO-PHARMA INC. (CA) | 2018-11-15 | — | — | WO | claimed |
| US-10123989-B2 | Method of lowering cholesterol | MED-LIFE DISCOVERIES LP (CA) | 2018-11-13 | — | — | US | claimed |
| US-20170056363-A1 | Method of lowering cholesterol | MED-LIFE DISCOVERIES LP (CA) | 2017-03-02 | — | — | US | claimed |
| US-9517222-B2 | Method for the treatment of senile dementia of the Alzheimer's type | PHENOMENOME DISCOVERIES INC. (CA) | 2016-12-13 | — | — | US | claimed |
| US-20160015673-A1 | METHOD FOR LOWERING CHOLESTEROL | MED-LIFE DISCOVERIES LP (CA) | 2016-01-21 | — | — | US | claimed |
| US-20150306057-A1 | METHOD FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER'S TYPE | MED-LIFE DISCOVERIES LP (CA) | 2015-10-29 | — | — | US | claimed |
| US-9034923-B2 | Methods for the treatment of senile dementia of the alzheimer's type | PHENOMENOME DISCOVERIES INC. (CA) | 2015-05-19 | — | — | US | claimed |
| WO-2008095275-A1 | METHODS FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER'S TYPE | PHENOMENOME DISCOVERIES INC. (CA) | 2008-08-14 | — | — | WO | claimed |
| CN-1110541-C | Concentrated water-dispersible stable fiber softener compositions | PROCTER & GAMBLE (US) | 2003-06-04 | — | — | CN | claimed |
| EP-0674646-B1 | LIPID DERIVATIVES OF PHOSPHONOACIDS FOR LIPOSOMAL INCORPORATION AND METHOD OF USE | CHIMERIX INC (US) | 2001-10-04 | — | — | EP | claimed |
| CN-1219953-A | Fabric softening compound/composition | PROCTER & GAMBLE (US) | 1999-06-16 | — | — | CN | claimed |
| CN-1196081-A | Concentrated, water dispersible, stable, fabric softening compositions | PROCTER & GAMBLE (US) | 1998-10-14 | — | — | CN | claimed |
| CN-1195369-A | Concentrated and stable fabric softening compositions | PROCTER & GAMBLE (US) | 1998-10-07 | — | — | CN | claimed |
| JP-H08504439-A | — | — | 1996-05-14 | — | — | JP | claimed |
| EP-0674646-A4 | LIPID DERIVATIVES OF PHOSPHONOACIDS FOR LIPOSOMAL INCORPORATION AND METHOD OF USE. | VESTAR INC (US) | 1996-01-17 | — | — | EP | claimed |
| EP-0674646-A1 | LIPID DERIVATIVES OF PHOSPHONOACIDS FOR LIPOSOMAL INCORPORATION AND METHOD OF USE | NeXstar Pharmaceuticals, Inc. (US) | 1995-10-04 | — | — | EP | claimed |
| WO-1994013682-A1 | LIPID DERIVATIVES OF PHOSPHONOACIDS FOR LIPOSOMAL INCORPORATION AND METHOD OF USE | VESTAR, INC. (US) | 1994-06-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015673-A1 | METHOD FOR LOWERING CHOLESTEROL | DLAT, SOAT2, CETP | CNR2 702/4885CNR1 869/4885ALDH1A1 807/4885 |
| US-20170056363-A1 | Method of lowering cholesterol | DLAT, SOAT2, CETP | CNR2 877/4885CNR1 1016/4885ALDH1A1 1163/4885 |
| US-20150306057-A1 | METHOD FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER'S TYPE | DLAT, HHAT, APP | CNR2 562/4885CNR1 745/4885ALDH1A1 686/4885 |
| US-10123989-B2 | Method of lowering cholesterol | CETP, HMGCR, LIPA | CNR2 2337/4885CNR1 2443/4885ALDH1A1 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.